Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OncoVEX^GM-CSF in Stage IIIc/IV Melanoma
NCT00289016Phase 2Completed
- Sponsor
- BioVex Group, Inc.
- Start
- Dec 2005
- Primary completion
- Dec 2008
- Modality
- Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec in Malignant Melanoma (MM), sponsored by BioVex Group, Inc. Primary endpoint: Objective Tumor Response Rate. Started Dec 2005; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00289016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00289016.